Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland, Portugal, Sweden, Switzerland). We report both the incidence and prevalence of AD for each country and the number of drug-treatment opportunities in each market.
Clarivate Epidemiology’s AD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with AD per year?
How will improvements in survival change the number of people living with a diagnosis of AD?
Of all people with AD, how many in each of the pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with AD, how many in each of the pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following AD subpopulations:
Total prevalent cases of asymptomatic AD.
Total prevalent cases of MCI due to AD by symptoms.
Total prevalent cases of symptomatic MCI due to AD by diagnosis status.
Total prevalent cases of AD.
Total prevalent cases of AD by severity (mild, moderate, severe).
Total prevalent cases of AD by diagnosis status.
Diagnosed prevalent cases of AD by symptom status (agitation, depression, psychosis).
Diagnosed prevalent cases of MCI due to AD by drug-treatment status
Diagnosed prevalent cases of AD by drug-treatment status.
Diagnosed prevalent cases of mild AD by drug-treatment status.
Diagnosed prevalent cases of moderate AD by drug-treatment status.
Diagnosed prevalent cases of severe AD by drug-treatment status.
Total Prevalence of Alzheimer's Disease per 1,000 People Aged 30+ in 2020 and 2040
Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Alzheimer's Disease Over the Next 20 Years
Total Prevalent Cases of Alzheimer's Disease by Severity
Number of Total Prevalent Cases of Alzheimer's Disease in 2040 Prevented in the Countries Under Study due to Trends in Riskttttttttt
Total Incident Cases of Asymptomatic Alzheimer's Disease
Multistate Model of the Progression of Alzheimer's Disease
Total Incident Cases of Mild Cognitive Impairment due to Alzheimer's Disease
Total Incident Cases of Alzheimer's Disease
Total Prevalent Cases of Asymptomatic Alzheimer's Disease
Total Prevalent Cases of Mild Cognitive Impairment due to Alzheimer's Disease
Total Prevalent Cases of Alzheimer's Disease
Total Prevalent Cases of Alzheimer's Disease by APOE e4 Status
Diagnosed Prevalent Cases of MCI due to Alzheimer's Disease and of Alzheimer's Disease
Diagnosed Prevalent Cases of Alzheimer's Disease by Severity
Diagnosed Prevalent Cases of Alzheimer's Disease by Symptom
Diagnosed and Drug-Treated Prevalent Cases of Alzheimer's Disease by Severity
Study Included in the Analysis of Alzheimer's Disease
Studies Excluded from the Analysis of Alzheimer's Disease
Risk/Protective Factors for Alzheimer's Disease
Oliver Blandy, M.Sc.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.